# DarioHealth Corp.: financial statements, quarterly

DRIO · Nasdaq · CIK 1533998 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/drio.md) · [Financials](/companies/drio/financials.md) · [Filings](/companies/drio/filings.md) · [Insiders](/companies/drio/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/drio/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [3.5](/filings/0001558370-24-014735.md) | [3.6 d](/filings/0001558370-25-002527.md) | [5.8](/filings/0001558370-25-007640.md) | [6.3](/filings/0001558370-25-011130.md) | [7.4](/filings/0001104659-25-110730.md) | [7.6 d](/filings/0001104659-26-031621.md) | [6.8](/filings/0001104659-26-059676.md) | [5.4](/filings/0001104659-26-093645.md) | [5.0](/filings/0001104659-25-110730.md) | [5.2 d](/filings/0001104659-26-031621.md) | [5.6](/filings/0001104659-26-059676.md) | [5.2](/filings/0001104659-26-093645.md) |
| Cost of revenue | $m | [2.9](/filings/0001558370-24-014735.md) | [3.5 d](/filings/0001558370-25-002527.md) | [3.3](/filings/0001558370-25-007640.md) | [3.5](/filings/0001558370-25-011130.md) | [3.5](/filings/0001104659-25-110730.md) | [3.4 d](/filings/0001104659-26-031621.md) | [2.9](/filings/0001104659-26-059676.md) | [2.4](/filings/0001104659-26-093645.md) | [2.0](/filings/0001104659-25-110730.md) | [2.4 d](/filings/0001104659-26-031621.md) | [2.4](/filings/0001104659-26-059676.md) | [2.0](/filings/0001104659-26-093645.md) |
| Gross profit | $m | [0.6](/filings/0001558370-24-014735.md) | [0.1 d](/filings/0001558370-25-002527.md) | [2.4](/filings/0001558370-25-007640.md) | [2.8](/filings/0001558370-25-011130.md) | [3.9](/filings/0001104659-25-110730.md) | [4.2 d](/filings/0001104659-26-031621.md) | [3.9](/filings/0001104659-26-059676.md) | [3.0](/filings/0001104659-26-093645.md) | [3.0](/filings/0001104659-25-110730.md) | [2.8 d](/filings/0001104659-26-031621.md) | [3.2](/filings/0001104659-26-059676.md) | [3.2](/filings/0001104659-26-093645.md) |
| Research and development | $m | [5.7](/filings/0001558370-24-014735.md) | [4.2 d](/filings/0001558370-25-002527.md) | [6.6](/filings/0001558370-25-007640.md) | [6.8](/filings/0001558370-25-011130.md) | [5.4](/filings/0001104659-25-110730.md) | [5.3 d](/filings/0001104659-26-031621.md) | [4.1](/filings/0001104659-26-059676.md) | [3.7](/filings/0001104659-26-093645.md) | [3.3](/filings/0001104659-25-110730.md) | [2.6 d](/filings/0001104659-26-031621.md) | [2.4](/filings/0001104659-26-059676.md) | [2.1](/filings/0001104659-26-093645.md) |
| Operating income | $m | [(15.5)](/filings/0001558370-24-014735.md) | [(14.2) d](/filings/0001558370-25-002527.md) | [(17.9)](/filings/0001558370-25-007640.md) | [(16.2)](/filings/0001558370-25-011130.md) | [(12.0)](/filings/0001104659-25-110730.md) | [(11.7) d](/filings/0001104659-26-031621.md) | [(9.4)](/filings/0001104659-26-059676.md) | [(9.2)](/filings/0001104659-26-093645.md) | [(9.5)](/filings/0001104659-25-110730.md) | [(8.6) d](/filings/0001104659-26-031621.md) | [(7.3)](/filings/0001104659-26-059676.md) | [(6.5)](/filings/0001104659-26-093645.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [1.2](/filings/0001104659-25-110730.md) | [1.1 d](/filings/0001104659-26-031621.md) | [1.1](/filings/0001104659-26-059676.md) | [1.1](/filings/0001104659-26-093645.md) |
| Income tax | $m | not reported | not reported | [0.0](/filings/0001558370-25-011130.md) | [(2.0) d](/filings/0001558370-25-011130.md) | [(0.0)](/filings/0001104659-25-110730.md) | [0.2 d](/filings/0001104659-26-031621.md) | [0.0](/filings/0001104659-26-059676.md) | [0.0](/filings/0001104659-26-093645.md) | [0.0](/filings/0001104659-25-110730.md) | [0.1 d](/filings/0001104659-26-031621.md) | [0.1](/filings/0001104659-26-059676.md) | [0.3](/filings/0001104659-26-093645.md) |
| Net income | $m | [(15.7)](/filings/0001558370-24-014735.md) | [(14.3) d](/filings/0001558370-25-002527.md) | [(7.2)](/filings/0001558370-25-007640.md) | [(13.6)](/filings/0001558370-25-011130.md) | [(12.3)](/filings/0001104659-25-110730.md) | [(9.6) d](/filings/0001104659-26-031621.md) | [(9.2)](/filings/0001104659-26-059676.md) | [(13.0)](/filings/0001104659-26-093645.md) | [(10.5)](/filings/0001104659-25-110730.md) | [(9.0) d](/filings/0001104659-26-031621.md) | [(8.2)](/filings/0001104659-26-059676.md) | [(7.9)](/filings/0001104659-26-093645.md) |
| Diluted EPS | $ per share | [0.49](/filings/0001558370-24-014735.md) | not reported | [0.20](/filings/0001558370-25-007640.md) | [0.08](/filings/0001558370-25-011130.md) | [4.91](/filings/0001104659-25-110730.md) | not reported | [2.87](/filings/0001104659-26-059676.md) | [3.54](/filings/0001104659-26-093645.md) | [2.96](/filings/0001104659-25-110730.md) | not reported | [1.25](/filings/0001104659-26-059676.md) | [0.85](/filings/0001104659-26-093645.md) |
| Basic EPS | $ per share | [0.49](/filings/0001558370-24-014735.md) | not reported | [0.20](/filings/0001558370-25-007640.md) | [0.08](/filings/0001558370-25-011130.md) | [4.91](/filings/0001104659-25-110730.md) | not reported | [2.87](/filings/0001104659-26-059676.md) | [3.54](/filings/0001104659-26-093645.md) | [2.96](/filings/0001104659-25-110730.md) | not reported | [1.25](/filings/0001104659-26-059676.md) | [0.85](/filings/0001104659-26-093645.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [43.9](/filings/0001558370-24-014735.md) | [36.8](/filings/0001558370-25-002527.md) | [34.4](/filings/0001558370-25-007640.md) | [22.9](/filings/0001558370-25-011130.md) | [15.5](/filings/0001104659-25-110730.md) | [27.8](/filings/0001104659-26-031621.md) | [27.9](/filings/0001558370-25-007640.md) | [22.0](/filings/0001558370-25-011130.md) | [31.9](/filings/0001104659-25-110730.md) | [21.8](/filings/0001104659-26-093645.md) | [15.0](/filings/0001104659-26-059676.md) | [6.6](/filings/0001104659-26-093645.md) |
| Current assets | $m | [56.2](/filings/0001558370-23-017301.md) | [47.3](/filings/0001558370-25-002527.md) | [52.5](/filings/0001544784-24-000067.md) | [39.3](/filings/0001558370-24-011453.md) | [29.5](/filings/0001558370-24-014735.md) | [40.5](/filings/0001104659-26-031621.md) | [38.6](/filings/0001558370-25-007640.md) | [32.2](/filings/0001558370-25-011130.md) | [42.2](/filings/0001104659-25-110730.md) | [35.1](/filings/0001104659-26-093645.md) | [28.7](/filings/0001104659-26-059676.md) | [22.1](/filings/0001104659-26-093645.md) |
| Total assets | $m | [107](/filings/0001558370-23-017301.md) | [96.4](/filings/0001558370-25-002527.md) | [137](/filings/0001544784-24-000067.md) | [122](/filings/0001558370-24-011453.md) | [110](/filings/0001558370-24-014735.md) | [119](/filings/0001104659-26-031621.md) | [116](/filings/0001558370-25-007640.md) | [108](/filings/0001558370-25-011130.md) | [118](/filings/0001104659-25-110730.md) | [110](/filings/0001104659-26-093645.md) | [103](/filings/0001104659-26-059676.md) | [96.6](/filings/0001104659-26-093645.md) |
| Current liabilities | $m | [8.1](/filings/0001558370-23-017301.md) | [12.5](/filings/0001558370-25-002527.md) | [17.8](/filings/0001544784-24-000067.md) | [17.4](/filings/0001558370-24-011453.md) | [18.8](/filings/0001558370-24-014735.md) | [16.6](/filings/0001104659-26-031621.md) | [19.2](/filings/0001558370-25-007640.md) | [9.8](/filings/0001558370-25-011130.md) | [9.3](/filings/0001104659-25-110730.md) | [9.3](/filings/0001104659-26-093645.md) | [9.4](/filings/0001104659-26-059676.md) | [9.6](/filings/0001104659-26-093645.md) |
| Long-term debt | $m | [29.0](/filings/0001558370-23-017301.md) | [24.6](/filings/0001558370-25-002527.md) | [24.5](/filings/0001544784-24-000067.md) | [23.4](/filings/0001558370-24-011453.md) | [20.2](/filings/0001558370-24-014735.md) | [23.5](/filings/0001104659-26-031621.md) | [18.9](/filings/0001558370-25-007640.md) | [30.5](/filings/0001558370-25-011130.md) | [30.6](/filings/0001104659-25-110730.md) | [30.7](/filings/0001104659-26-093645.md) | [30.9](/filings/0001104659-26-059676.md) | [31.1](/filings/0001104659-26-093645.md) |
| Current portion of debt | $m | not reported | [4.0](/filings/0001558370-25-002527.md) | [4.0](/filings/0001544784-24-000067.md) | [5.2](/filings/0001558370-24-011453.md) | [8.7](/filings/0001558370-24-014735.md) | [5.5](/filings/0001104659-26-031621.md) | [10.3](/filings/0001558370-25-007640.md) | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [68.0](/filings/0001558370-24-014735.md) | [58.1](/filings/0001104659-26-031621.md) | [78.0](/filings/0001558370-25-011130.md) | [68.1](/filings/0001104659-25-110730.md) | [58.5](/filings/0001104659-25-110730.md) | [72.0](/filings/0001104659-26-093645.md) | [73.7](/filings/0001104659-26-093645.md) | [64.0](/filings/0001104659-26-093645.md) | [74.9](/filings/0001104659-25-110730.md) | [67.9](/filings/0001104659-26-093645.md) | [62.4](/filings/0001104659-26-093645.md) | [55.1](/filings/0001104659-26-093645.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(8.6) d](/filings/0001558370-24-014735.md) | [(7.3) d](/filings/0001558370-25-002527.md) | [(13.1)](/filings/0001558370-25-007640.md) | [(11.4) d](/filings/0001558370-25-011130.md) | [(7.4) d](/filings/0001104659-25-110730.md) | [(6.7) d](/filings/0001104659-26-031621.md) | [(6.7)](/filings/0001104659-26-059676.md) | [(6.0) d](/filings/0001104659-26-093645.md) | [(7.4) d](/filings/0001104659-25-110730.md) | [(5.9) d](/filings/0001104659-26-031621.md) | [(6.0)](/filings/0001104659-26-059676.md) | [(6.1) d](/filings/0001104659-26-093645.md) |
| Capital expenditure | $m | [0.3 d](/filings/0001558370-24-014735.md) | [0.1 d](/filings/0001558370-25-002527.md) | [0.1](/filings/0001558370-25-007640.md) | [0.0 d](/filings/0001558370-25-011130.md) | [0.0 d](/filings/0001104659-25-110730.md) | [0.0 d](/filings/0001104659-26-031621.md) | [0.0](/filings/0001104659-26-059676.md) | [0.0 d](/filings/0001104659-26-093645.md) | [0.0 d](/filings/0001104659-25-110730.md) | [0.0 d](/filings/0001104659-26-031621.md) | [0.0](/filings/0001104659-26-059676.md) | [0.0 d](/filings/0001104659-26-093645.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [23.0](/filings/0001558370-23-017301.md) | [27.6](/filings/0001544784-24-000067.md) | [28.2](/filings/0001558370-24-011453.md) | [28.8](/filings/0001558370-24-014735.md) | [34.4](/filings/0001558370-25-007640.md) | [39.8](/filings/0001558370-25-011130.md) | [2.0](/filings/0001104659-25-110730.md) | [2.4](/filings/0001104659-26-059676.md) | [2.5](/filings/0001104659-26-093645.md) | [3.1](/filings/0001104659-25-110730.md) | [6.6](/filings/0001104659-26-059676.md) | [9.3](/filings/0001104659-26-093645.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 9,799,481 at 2026-08-11, from the cover of the [10-Q filed 2026-08-11](/filings/0001104659-26-093645.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.